|Articles|October 24, 2022
How CDMOs Can Support Nanoparticles for Gene Therapy, Immuno-Oncology, and Vaccines
Author(s)Emergent CDMO
Many CDMOs outsource their nanoparticle supply chain, but in house manufacturing of nanoparticles at CDMOs is anticipated to create new market opportunities.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
4
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
5